About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, announced new data from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. The study will be presented today, Jan. 25, ...

Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial Colorectal cancer (CRC ... may help guide the ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...

The market is responding to this breakthrough. Analysts at Exactitude Consultancy predict that the global immunotherapy ...

1Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. 2Medical Faculty, University Duisburg-Essen, Essen, Germany. 3National Center of Tumor Diseases ...

McKenzie, a Certified Sleep Science Coach and proclaimed mattress expert, has been writing sleep content in the wellness space for over four years. After earning her certification from the Spencer ...

The following is a summary of “Introducing Neoadjuvant Immunotherapy for Colorectal Cancer: Advancing the Frontier,” published in the January 2025 issue of Surgery by Orhan et al. Immunotherapy, ...

Cancer immunotherapy drugs, which boost the immune system to fight the tumor, have revolutionised the treatment of the deficient subtype of colorectal cancer. However, these drugs only work in ...

Opens in a new tab or window Treating patients with aspirin after completion of standard adjuvant therapy for colorectal cancer failed to significantly improve disease-free survival (DFS ...